ARVN - Arvinas Inc logo

ARVN

Arvinas Inc

Arvinas Inc develops therapies that utilize protein degradation to treat various diseases. Its pipeline includes treatments for neurodegenerative diseases, cancers with specific mutations, and breast cancer, relying on innovative PROTAC technology.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$99today

Score Overview

1 Year
Score
Net Growth111.51%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth20.60%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score6.2
Net Growth105.08%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth6x
Rev Trend60%
Revenue Consistencyโ€”
All Time
Score
Net Growth122.42%
Net Trend38%
Net Income Consistency
Rev Growth22x
Rev Trend63%
Revenue Consistency

See the full market ranking โ†’

Arvinas Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 21M to $ 262M and net income went from -$ 111M to -$ 80M. Revenue increased in 3 of those 5 years; net income in 3.

Arvinas Inc currently holds a 5-year HDB Score of 6.2 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 8.87โ€”
1 Year2025-08-12
$ 6.7930.63%
5 Years2021-08-12
$ 90.04-90.15%
All Time2018-09-27
$ 16.05-44.74%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 316M$ 9M$ 567M
2025$ 262M-$ 80M$ 685M
2024$ 263M-$ 198M$ 1.03B
2023$ 78M-$ 367M$ 1.26B
2022$ 131M-$ 271M$ 1.20B
2021$ 46M-$ 183M$ 1.50B
2020$ 21M-$ 111M$ 688M
2019$ 42M-$ 62M$ 280M
IPO2018$ 14M-$ 41M$ 187M

Explore beyond ARVN

You're looking at Arvinas Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies